Anti-breast cancer effects of phytochemicals: primary,
secondary, and tertiary care

J 2022

Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care

MAZURAKOVA, Alena, Lenka KOKLESOVA, Marek SAMEC, Erik KUDELA, Karol KAJO et. al.

Základní údaje

Originální název

Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care

Autoři

Vydání

EPMA JOURNAL, Cham, SPRINGER INT PUBL AG, 2022, 1878-5077

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.500

Kód RIV

RIV/00216224:14160/22:00129768

Organizační jednotka

Farmaceutická fakulta

DOI

http://dx.doi.org/10.1007/s13167-022-00277-2

UT WoS

000782529800001

Klíčová slova anglicky

Breast cancer; Phytochemicals; Individualized patient profiling; Modifiable risk factors; Health risk assessment; Molecular patterns; Predictive Preventive Personalized Medicine (PPPM/3PM); Primary secondary tertiary care; Treated cancer; COVID-19

Štítky

rivok, ÚPL

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 20. 4. 2023 17:05, JUDr. Sabina Krejčiříková

Anotace

V originále

Breast cancer incidence is actually the highest one among all cancers. Overall breast cancer management is associated with challenges considering risk assessment and predictive diagnostics, targeted prevention of metastatic disease, appropriate treatment options, and cost-effectiveness of approaches applied. Accumulated research evidence indicates promising anti-cancer effects of phytochemicals protecting cells against malignant transformation, inhibiting carcinogenesis and metastatic spread, supporting immune system and increasing effectiveness of conventional anti-cancer therapies, among others. Molecular and sub-/cellular mechanisms are highly complex affecting several pathways considered potent targets for advanced diagnostics and cost-effective treatments. Demonstrated anti-cancer affects, therefore, are clinically relevant for improving individual outcomes and might be applicable to the primary (protection against initial cancer development), secondary (protection against potential metastatic disease development), and tertiary (towards cascading complications) care. However, a detailed data analysis is essential to adapt treatment algorithms to individuals’ and patients’ needs. Consequently, advanced concepts of patient stratification, predictive diagnostics, targeted prevention, and treatments tailored to the individualized patient profile are instrumental for the cost-effective application of natural anti-cancer substances to improve overall breast cancer management benefiting affected individuals and the society at large.

Citovat

MAZURAKOVA, Alena, Lenka KOKLESOVA, Marek SAMEC, Erik KUDELA, Karol KAJO, Veronika SKUCIOVA, Sandra Hurta CSIZMAR, Veronika MESTANOVA, Martin PEC, Marian ADAMKOV, Raghad Khalid AL-ISHAQ, Karel ŠMEJKAL, Frank A GIORDANO, Dietrich BUSSELBERG, Kamil BIRINGER, Olga GOLUBNITSCHAJA a Peter KUBATKA. Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care. EPMA JOURNAL. Cham: SPRINGER INT PUBL AG, 2022, roč. 13, č. 2, s. 315-334. ISSN 1878-5077. Dostupné z: https://dx.doi.org/10.1007/s13167-022-00277-2.

@article{2276485,
   author = {Mazurakova, Alena and Koklesova, Lenka and Samec, Marek and Kudela, Erik and Kajo, Karol and Skuciova, Veronika and Csizmar, Sandra Hurta and Mestanova, Veronika and Pec, Martin and Adamkov, Marian and AlandIshaq, Raghad Khalid and Šmejkal, Karel and Giordano, Frank A and Busselberg, Dietrich and Biringer, Kamil and Golubnitschaja, Olga and Kubatka, Peter},
   article_location = {Cham},
   article_number = {2},
   doi = {http://dx.doi.org/10.1007/s13167-022-00277-2},
   keywords = {Breast cancer; Phytochemicals; Individualized patient profiling; Modifiable risk factors; Health risk assessment; Molecular patterns; Predictive Preventive Personalized Medicine (PPPM/3PM); Primary secondary tertiary care; Treated cancer; COVID-19},
   language = {eng},
   issn = {1878-5077},
   journal = {EPMA JOURNAL},
   title = {Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care},
   url = {https://link.springer.com/article/10.1007/s13167-022-00277-2},
   volume = {13},
   year = {2022}
}

TY  - JOUR
ID  - 2276485
AU  - Mazurakova, Alena - Koklesova, Lenka - Samec, Marek - Kudela, Erik - Kajo, Karol - Skuciova, Veronika - Csizmar, Sandra Hurta - Mestanova, Veronika - Pec, Martin - Adamkov, Marian - Al-Ishaq, Raghad Khalid - Šmejkal, Karel - Giordano, Frank A - Busselberg, Dietrich - Biringer, Kamil - Golubnitschaja, Olga - Kubatka, Peter
PY  - 2022
TI  - Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care
JF  - EPMA JOURNAL
VL  - 13
IS  - 2
SP  - 315-334
EP  - 315-334
PB  - SPRINGER INT PUBL AG
SN  - 18785077
KW  - Breast cancer
KW  - Phytochemicals
KW  - Individualized patient profiling
KW  - Modifiable risk factors
KW  - Health risk assessment
KW  - Molecular patterns
KW  - Predictive Preventive Personalized Medicine (PPPM/3PM)
KW  - Primary secondary tertiary care
KW  - Treated cancer
KW  - COVID-19
UR  - https://link.springer.com/article/10.1007/s13167-022-00277-2
N2  - Breast cancer incidence is actually the highest one among all cancers. Overall breast cancer management is associated with challenges considering risk assessment and predictive diagnostics, targeted prevention of metastatic disease, appropriate treatment options, and cost-effectiveness of approaches applied. Accumulated research evidence indicates promising anti-cancer effects of phytochemicals protecting cells against malignant transformation, inhibiting carcinogenesis and metastatic spread, supporting immune system and increasing effectiveness of conventional anti-cancer therapies, among others. Molecular and sub-/cellular mechanisms are highly complex affecting several pathways considered potent targets for advanced diagnostics and cost-effective treatments. Demonstrated anti-cancer affects, therefore, are clinically relevant for improving individual outcomes and might be applicable to the primary (protection against initial cancer development), secondary (protection against potential metastatic disease development), and tertiary (towards cascading complications) care. However, a detailed data analysis is essential to adapt treatment algorithms to individuals’ and patients’ needs. Consequently, advanced concepts of patient stratification, predictive diagnostics, targeted prevention, and treatments tailored to the individualized patient profile are instrumental for the cost-effective application of natural anti-cancer substances to improve overall breast cancer management benefiting affected individuals and the society at large.
ER  -

MAZURAKOVA, Alena, Lenka KOKLESOVA, Marek SAMEC, Erik KUDELA, Karol KAJO, Veronika SKUCIOVA, Sandra Hurta CSIZMAR, Veronika MESTANOVA, Martin PEC, Marian ADAMKOV, Raghad Khalid AL-ISHAQ, Karel ŠMEJKAL, Frank A GIORDANO, Dietrich BUSSELBERG, Kamil BIRINGER, Olga GOLUBNITSCHAJA a Peter KUBATKA. Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care. \textit{EPMA JOURNAL}. Cham: SPRINGER INT PUBL AG, 2022, roč.~13, č.~2, s.~315-334. ISSN~1878-5077. Dostupné z: https://dx.doi.org/10.1007/s13167-022-00277-2.

Podrobný výpis o publikaci